Patient, N
|
267
|
26
| |
Sex
|
Women, n (%)
|
145 (54%)
|
11 (52%)
|
0.24
|
Age, mean +/− sd
|
80+/−11.1
|
80+/−10.5
|
0.98
|
> 65 years, n (%)
|
237 (88%)
|
24 (92%)
|
0.75
|
> 75 years, n (%)
|
209 (78%)
|
19 (73%)
|
0.54
|
Medical history, n (%)
|
Stroke
|
61 (22%)
|
8 (32%)
|
0.30
|
Cancer
|
36 (13%)
|
4 (15%)
|
0.76
|
Major bleeding
|
9 (3%)
|
4 (15%)
|
0.02
|
Risk of falling
|
149 (55%)
|
19 (73%)
|
0.10
|
Renal or hepatic failure
|
69 (25%)
|
5 (19%)
|
0.45
|
Hypertension
|
158 (63%)
|
18 (75%)
|
0.24
|
Antiplatelet, n (%)
|
ASA alone
|
199 (74.5%)
|
17 (65.4%)
|
0.31
|
Clopidogrel alone
|
46 (17.2%)
|
4 (15.4%)
|
0.81
|
ASA + clopidogrel
|
18 (6%)
|
5 (19%)
|
0.04
|
ASA + anti-Gp2b3a
|
4 (1.5%)
|
0 (0%)
|
1
|
Clinical characteristics, n (%)
|
High-energy trauma
|
35 (13%)
|
5 (19%)
|
0.37
|
Alcohol
|
13 (4%)
|
0 (0%)
|
0.61
|
Loss of consciousness or amnesia
|
103 (38.5%)
|
19 (73%)
|
< 0.001
|
Headache or vomiting
|
26 (9.7%)
|
9 (34.6%)
|
< 0.001
|
Glasgow coma scale, median (IQR)
|
15 [15–15]
|
14 [13–15]
|
< 0.001
|
Biological characteristics, n (%)
|
Anemia
|
67 (27%)
|
8 (30%)
|
0.68
|
Thrombocytopenia
|
23 (9%)
|
2 (8%)
|
1
|
CrCl ml/min, median (IQR)
|
66 [51–84]
|
65 [52–77]
|
0.72
|